PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor

Nilotinib is a second-generation tyrosine kinase inhibitor, designed to specifically inhibit break-point cluster region (BCR)-Abelson (ABL) and developed to treat chronic myeloid leukemia (CML) in patients showing a resistance to imatinib. We previously demonstrated that nilotinib-induced apoptosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Airiau, K, Mahon, F-X, Josselin, M, Jeanneteau, M, Belloc, F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824646/
https://www.ncbi.nlm.nih.gov/pubmed/24091670
http://dx.doi.org/10.1038/cddis.2013.309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824646/
https://www.ncbi.nlm.nih.gov/pubmed/24091670
http://dx.doi.org/10.1038/cddis.2013.309

Ejemplares similares